RESUMO
Previously, we reported that heat shock protein (HSP)65 impairs the effects of high-density lipoprotein on macrophages. We also showed that immune response activation adversely affects reverse cholesterol transport (RCT). In this study, we investigated the effects of the Src family kinase lymphocyte-specific protein tyrosine kinase (Lck) and elucidated the mechanism underlying HSP65-regulated cholesterol efflux in T cells. We evaluated cell proliferation, Lck expression, and inflammatory cytokine production in Jurkat cells and CD4+ T cells. HSP65-mediated inhibition of RCT was assessed by evaluating ABCA1, ABCG1, SR-BI, PPAR-γ, and liver X receptor-α expression. A dose-dependent relationship was found between the levels of these proteins and the suppression of cholesterol efflux. Stimulation of Lck-silenced T cells with ionomycin resulted in a decrease in intracellular calcium levels. Treatment of Jurkat cells with PP2, an inhibitor of Src family kinase, inhibited calcium-induced, but not PMA-induced, ERK phosphorylation. NF-κB activation in response to PMA was minimally inhibited in cells stimulated with PP2. HSP65 failed to trigger downstream ERK or JNK phosphorylation or to activate NF-κB or protein kinase C-γ in Lck-silenced cells. Additionally, elevation of intracellular calcium was also impaired. However, HSP65 significantly enhanced cholesterol efflux and decreased cellular cholesterol content by inducing the expression of cholesterol transport proteins in Lck-silenced cells. The treatment of Jurkat cells with PP2 also inhibited cell proliferation and promoted RCT. In conclusion, Lck is a key molecule in the TCR signaling cascade that inhibits cholesterol efflux and upregulates intracellular cholesterol ester content in T cells. Our results demonstrate that the immune response plays a previously unrecognized role in RCT.
Assuntos
Linfócitos T CD4-Positivos/imunologia , Linfócitos T CD4-Positivos/metabolismo , Colesterol/metabolismo , Proteínas de Choque Térmico/metabolismo , Proteína Tirosina Quinase p56(lck) Linfócito-Específica/metabolismo , Linfócitos T/imunologia , Linfócitos T/metabolismo , Transportador 1 de Cassete de Ligação de ATP/genética , Membro 1 da Subfamília G de Transportadores de Cassetes de Ligação de ATP/genética , Transporte Biológico/efeitos dos fármacos , Cálcio/metabolismo , Proliferação de Células/efeitos dos fármacos , Citocinas/imunologia , Proteínas de Choque Térmico/genética , Humanos , Inflamação/imunologia , Ionomicina/farmacologia , Células Jurkat , Ativação Linfocitária , Proteína Tirosina Quinase p56(lck) Linfócito-Específica/genética , Sistema de Sinalização das MAP Quinases/efeitos dos fármacos , NF-kappa B/imunologia , PPAR gama/genética , Fosforilação/efeitos dos fármacos , Pirimidinas/farmacologia , Receptores de Antígenos de Linfócitos T/metabolismo , Receptores Depuradores Classe B/genética , Transdução de Sinais/efeitos dos fármacos , Linfócitos T/efeitos dos fármacosRESUMO
Great advances are being made in the understanding of the structural and functional diversity of high-density lipoprotein at the mechanistic level. High-density lipoprotein possesses numerous physiological activities, the most studied of which is the ability to promote excess cholesterol efflux from peripheral tissues to the liver for excretion via a mechanism believed to confer protection against atherosclerosis. Accumulating evidence has demonstrated that atherosclerosis is a chronic inflammatory response. Recent studies have suggested that high-density lipoprotein possesses anti-inflammatory properties and regulates both innate and adaptive immune responses. However, further complicating this very complex system is the ï¬nding that inflammation, via alteration of the proteomic and lipidomic composition of high-density lipoprotein species, can modulate at least some of their functional activities. Modified high-density lipoprotein exhibits a reduced ability to mediate cholesterol efflux from peripheral tissues and to inhibit cytokine-induced adhesion molecule expression and even promotes the occurrence of inflammation. This review focuses on the underlying mechanism of the interaction between high-density lipoprotein and inflammation to clarify the pathologic process of atherosclerosis.
Assuntos
Aterosclerose/imunologia , Inflamação/metabolismo , Lipoproteínas HDL/imunologia , Animais , Humanos , Inflamação/complicações , Lipoproteínas HDL/metabolismoRESUMO
Serum amyloid P-component (SAP) contributes to host defense and prevents fibrosis. Macrophages are the most abundant inflammatory cell type in atherosclerotic plaques. In the present study, using (3)H-cholesterol-labeled counting radioactivity assay, we demonstrated that the apoAI-mediated cholesterol efflux in RAW264.7 macrophages was increased by SAP treatment in a time- and dose-dependent manner. We analyzed global gene expression changes upon SAP treatment using RNA sequencing. As a result, a total of 175 differentially expressed genes were identified, of which 134 genes were downregulated and 41 genes were upregulated in SAP treated cells compared to control cells. Quantitative RT-PCR analysis confirmed decreased expression of 5 genes and an increase in expression of 1 gene upon SAP treatment. Gene ontology analysis showed that genes involved in response to stimulus were significantly enriched in differentially expressed genes. Beyond protein-coding genes, we also identified 8 differentially expressed long noncoding RNAs. Our study may provide new insights into mechanisms underlying the functional role of SAP in macrophages.
Assuntos
Apolipoproteína A-I/imunologia , Colesterol/imunologia , Regulação da Expressão Gênica/imunologia , Componente Amiloide P Sérico/administração & dosagem , Componente Amiloide P Sérico/imunologia , Animais , Regulação da Expressão Gênica/efeitos dos fármacos , Camundongos , Células RAW 264.7RESUMO
Hypoxia-induced cardiomyocyte apoptosis contributes significantly to the development of numerous cardiac diseases, such as ischemic heart disease, heart failure, etc. Promoting cell survival by inhibiting apoptosis is one of the available strategies to attenuate cardiac dysfunction caused by cardiomyocyte loss. Previous studies have been demonstrated that miR-138 and lipocalin-2 (Lcn2) play important roles in cardiomyocyte apoptosis and survival. We presently determined whether Lcn2 is a target gene of miR-138 involved in hypoxia-induced cardiomyocyte apoptosis. Firstly, mimics of miR-138 were transfected into HL-1 cells to investigate its effect on cell apoptosis. Using 3-(4,5-dimethyl-thiazol-2-y1) 2,5-diphenyl tetrazolium bromide (MTT) and Annexin V-FITC/PI flow cytometer assays, over-expression of miR-138 significantly enhanced the cell growth and significantly attenuated the cell apoptosis in hypoxic conditions. Dual-luciferase reporter gene and western blot results confirmed Lcn2 was a direct target of miR-138. Then, the recombinant plasmid, pcDNA3.1/Lcn2 was transfected into the HL-1 cells that over-expressed miR-138. We further observed that the over-expression of Lcn2 diminished the protection of miR-138 over-expression from hypoxia-induced cell survival and apoptosis. In conclusion, our study demonstrated that up-regulation of miR-138 inhibits the hypoxia-induced cardiomyocyte apoptosis via down-regulating the pro-apoptotic gene expression of Lcn2.
Assuntos
Proteínas de Fase Aguda/antagonistas & inibidores , Proteínas de Fase Aguda/biossíntese , Apoptose , Hipóxia/patologia , Lipocalinas/antagonistas & inibidores , Lipocalinas/biossíntese , MicroRNAs/metabolismo , Miócitos Cardíacos/fisiologia , Proteínas Oncogênicas/antagonistas & inibidores , Proteínas Oncogênicas/biossíntese , Animais , Western Blotting , Sobrevivência Celular , Regulação para Baixo , Perfilação da Expressão Gênica , Genes Reporter , Lipocalina-2 , Luciferases/análise , Luciferases/genética , CamundongosRESUMO
BACKGROUND: Restenosis after percutaneous coronary intervention (PCI) is a remained clinical problem which limits long-term success of PCI. Although there was recognition that probucol in treating restenosis after percutaneous transluminal coronary angioplasty, the efficacy of probucol on restenosis after stent-implantation is controversial. So this meta-analysis was conducted to investigate the association between probucol and late restenosis. METHODS: Articles were assessed by four trained investigators, with divergences resolved by consensus. PubMed, EMBASE, ScienceDirect and the Cochrane Central Register of clinical trials were searched for pertinent studies. Inclusion criteria were random allocated to treatment and a comparison of probucol-treated patients and control patients (not treated with lipid-lowering drug) undergoing PCI. RESULTS: Fifteen studies with 859 subjects were analyzed. Major outcome, binary angiographic restenosis defined as >50% stenosis upon follow-up angiography, was significantly decreased with probucol treatment (RR = 0.59 [0.43, 0.80] among vessels, P = 0.0007; and RR = 0.52 [0.40, 0.68] among patients, P<0.00001). Probucol also increased the minimal luminal diameter (SMD = 0.45 [0.30, 0.61], P<0.00001) and decreased late loss upon follow-up after 6 months (SMD = -0.41 [-0.60, -0.22], P<0.0001). Moreover, there was a significantly lower incidence of major adverse cardiac events (MACE) in the probucol group than control group (RR = 0.69 [0.51, 0.93], P = 0.01). CONCLUSION: Probucol is more than a lipid-lowering drug. It is also effective in reducing the risk of restenosis and incidence of MACE after PCI.
Assuntos
Anticolesterolemiantes/uso terapêutico , Fármacos Cardiovasculares/uso terapêutico , Doença das Coronárias/terapia , Probucol/uso terapêutico , Anticolesterolemiantes/farmacologia , Fármacos Cardiovasculares/farmacologia , Terapia Combinada , Humanos , Intervenção Coronária Percutânea , Probucol/farmacologia , Resultado do TratamentoRESUMO
Serum amyloid P component (SAP), also known as pentraxin-2, is a member of the pentraxin protein family with an established relationship to the immune response. In the last century, SAP has been used as a diagnostic marker in amyloidosis diagnosis and patient follow-up. SAP has been thought to have potential for treating and curing amyloidosis and fibrosis diseases. More recently, it has been shown that SAP may serve as both a diagnostic marker and a therapeutic target for many immune-related diseases, such as cardiovascular, pulmonary, nephritic, neurological and autoimmune diseases. In the cardiovascular system, SAP has been defined as the culprit in amyloidosis in the heart. SAP may also exert a protective role during the early stage of atherosclerosis and myocardial fibrosis. In noncardiovascular system diseases, SAP is being developed for the treatment of pulmonary fibrosis. In this review, we summarize SAP history, structure, and its roles in immune-related diseases in different systems with emphasis on the cardiovascular system.